CAMBRIDGE, Mass.— NextPoint Therapeutics, a clinical-stage biotechnology company specializing in precision cancer treatments, announced it will present new preclinical findings at the American Association for Cancer Research (AACR) Annual Meeting, taking place in Chicago from April 25–30, 2025.
The company will unveil four research posters highlighting its novel oncology pipeline targeting the B7-H7 immune pathway. This includes promising developments in two key therapeutic approaches: a B7-H7-targeted antibody-drug conjugate (ADC) utilizing proprietary linker technology, and a B7-H7-CD3 bispecific T cell engager (TCE) designed with a wide therapeutic window.
B7-H7 is a checkpoint protein found to be highly expressed on a range of tumor cells but with minimal presence in normal tissues—making it an attractive target for cancer immunotherapy. The preclinical data being presented will demonstrate the efficacy of these first-in-class therapies across multiple solid tumor types, along with comprehensive tumor expression analyses that inform NextPoint’s biomarker-driven patient selection strategy.
“These findings reinforce the potential of our B7-H7-targeted therapies to deliver more effective and selective treatment options for patients with solid tumors,” said the company in a statement.
NextPoint’s presentations aim to underline the company’s leadership in advancing precision immunotherapies that engage the immune system with high specificity and reduced toxicity.
